Other languages Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Market Closed - Nasdaq Other stock markets 02:00:00 27/04/2024 am IST			5-day change	1st Jan Change
0.3427 ^USD	+0.76%		+6.73%	-43.82%

21/03	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/01	Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	05/01
Top Premarket Gainers	05/01
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	21/12
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	17/11
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million	17/11
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	16/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	27/23/27
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	08/23/08
Dermata Therapeutics Completes $1.8 Million Share Offering	27/23/27
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected	12/23/12
US Futures Trend Higher Ahead of Import/Export Data, Consumer Sentiment Survey Results	12/23/12
Top Premarket Gainers	12/23/12
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Weak Corporate Earnings Weigh on Sentiment, Fueling Premarket Losses for US Equity Futures	20/23/20
Top Premarket Gainers	20/23/20
Top Premarket Gainers	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Other languages

Filters